Enceladus Pharmaceuticals BV   Report issue

For profit Phase 2
Founded: Amsterdam Netherlands (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2017
NCT03033316
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1